BioteBTMD -8.21%66 Days Payable is 49.15 as of Mar. 2026, which is 81% above its 10-year median of 27.18. GuruFocus rates BTMD with a GF Score™ of 66/100 and a GF Value™ of $3.07 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Biote ranks worse than 69.64% on this metric.
Biote's average Accounts Payable for the
three
months ended in Mar. 2026 was $7.5 Mil. Biote's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $14.0 Mil.
Hence, Biote's Days Payable for the
three
months ended in Mar. 2026 was 49.15.
The historical rank and industry rank for Biote's Days Payable or its related term are showing as below:
BTMD'
s Days Payable Range Over the Past 10 Years
Min: 19.86 Med: 27.18 Max: 42.05
Current: 34.56
During the past 7 years, Biote's highest Days Payable was 42.05. The lowest was 19.86. And the median was 27.18.
BTMD's Days Payable is ranked worse than 69.64% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs BTMD: 34.56
Biote's Days Payable
increased
from Mar. 2025 (33.10) to Mar. 2026 (49.15).
It may suggest that Biotedelayed paying its suppliers.
Biote Days Payable Related Terms
Biote Days Payable Historical Data
* Premium members only.
The historical data trend for Biote's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Biote's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biote Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Biote's Days Payable distribution charts can be found below:
* The bar in red indicates where Biote's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biote's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biote (BTMD) has a Days Payable of 49.15 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biote and its competitors. This is 81% above median its historical median of 27.18. Over the past decade, Biote's Days Payable has ranged from 19.86 to 42.05. According to the industry distribution chart, Biote ranks #422 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 69.6%.
Is Biote's Days Payable too high?
Biote's current Days Payable of 49.15 is 81% above median its 10-year median of 27.18. Over the past 10 years, this metric has ranged from a low of 19.86 to a high of 42.05. The Healthcare Providers & Services industry median Days Payable is 58.21. Biote's value of 49.15 is 15.6% below this industry median. Based on the distribution chart, Biote ranks #422 out of 606 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Biote has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biote's Days Payable compare to DCGO and PIII?
According to the Healthcare Providers & Services industry distribution chart, Biote ranks #422 out of 606 companies for Days Payable. This places Biote in the lower half of its industry. The industry median Days Payable is 58.21. Biote's value of 49.15 is 15.6% below this benchmark. Historically, Biote's own Days Payable has ranged from 19.86 to 42.05 over the past decade. While the company's 10-year median is 27.18 vs. the industry median of 58.21, Biote has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biote's current Days Payable of 49.15 is 15.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biote and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biote's current Days Payable is 49.15, which is 81% above median its own 10-year median of 27.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biote stock overvalued right now?
Based on GuruFocus' analysis, Biote (BTMD) is currently considered Significantly Undervalued. The stock's GF Value™ is $3.07, compared to a current price of $1.81 — trading 41.2% below its estimated fair value. The current Days Payable is 49.15, which is 81% above median its 10-year median of 27.18 and 15.6% below the Healthcare Providers & Services industry median of 58.21. Biote's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biote (BTMD), the current Days Payable is 49.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biote (BTMD) Overvalued in 2026?
Based on GuruFocus' analysis, Biote stock appears to be undervalued.
The current stock price of $1.81 is trading 41.2% below its estimated GF Value™ of $3.07.
GuruFocus considers Biote to be Significantly Undervalued.
Key valuation signals for BTMD:
Days Payable: 49.15 (81% above median its 10-year median of 27.18)
GF Value™: $3.07 vs. price of $1.81 (41.2% below fair value)
Industry Position: 15.6% below the Healthcare Providers & Services median (#422 of 606)
No single metric tells the full story. See the BTMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
66GF Score
Get the complete analysis for BTMD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTMD has been successfully added to your 
